Literature DB >> 1560164

The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours.

E Y Derom1, R A Pauwels, M E Van der Straeten.   

Abstract

The duration of the protective effect of 50 and 100 micrograms of inhaled salmeterol against methacholine-induced bronchoconstriction was compared with that of 200 micrograms of inhaled salbutamol in 12 patients with asthma with a baseline FEV1 of at least 70% and a provocative concentration of inhaled methacholine causing a 20% fall in FEV1 (PC20) greater than or equal to 8 mg/ml. The study was placebo controlled, double blind, randomized, and crossover. The bronchodilating effect was no longer significant 4 hours after inhalation of salbutamol, whereas the effect was still present 12 hours after administration of 50 and 100 micrograms of salmeterol. All active treatments caused PC20 to increase at 1 hour (p less than 0.05). PC20 (milligrams per milliliter) thus reached 3.7 +/- 0.8 after placebo, 13.8 +/- 3.0 after 50 micrograms of salmeterol, 23.2 +/- 4.7 after 100 micrograms of salmeterol, and 13.9 +/- 3.4 after 200 micrograms of salbutamol. The protective effect of 200 micrograms of salbutamol was no longer significant at 4 hours, whereas both doses of salmeterol protected against methacholine challenge up to 12 hours after inhalation (p less than 0.01). An increased incidence of tremor (2/12) and palpitations (2/12) was recorded after inhalation of 100 micrograms of salmeterol. We conclude that inhalation of 50 or 100 micrograms of salmeterol causes a long-lasting bronchodilatation and protects against methacholine-induced bronchoconstriction for at least 12 hours.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560164     DOI: 10.1016/0091-6749(92)90435-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  16 in total

Review 1.  Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

Authors:  E H Walters; J A Walters; P W Gibson
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 2.  Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Authors:  J C Adkins; D McTavish
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 3.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

4.  Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products.

Authors:  Leslie Hendeles; Peter T Daley-Yates; Robert Hermann; Jan De Backer; Sanjeeva Dissanayake; Stephen T Horhota
Journal:  AAPS J       Date:  2015-02-26       Impact factor: 4.009

5.  Utilization, spending, and price trends for short- and long-acting Beta-agonists and inhaled corticosteroids in the medicaid program, 1991-2010.

Authors:  Shih-Feng Chiu; Christina M L Kelton; Jeff Jianfei Guo; Patricia R Wigle; Alex C Lin; Sheryl L Szeinbach
Journal:  Am Health Drug Benefits       Date:  2011-05

6.  Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma.

Authors:  M A Higham; A M Sharara; P Wilson; R J Jenkins; G A Glendenning; P W Ind
Journal:  Thorax       Date:  1997-11       Impact factor: 9.139

Review 7.  Inhaled beta-2 agonists and steroids. Present state and future perspectives.

Authors:  A M Clauzel
Journal:  Clin Rev Allergy       Date:  1994

8.  Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma.

Authors:  E T Smyth; I D Pavord; C S Wong; A F Wisniewski; J Williams; A E Tattersfield
Journal:  BMJ       Date:  1993-02-27

9.  Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients.

Authors:  H Booth; K Fishwick; R Harkawat; G Devereux; D J Hendrick; E H Walters
Journal:  Thorax       Date:  1993-11       Impact factor: 9.139

Review 10.  Salmeterol: an inhaled beta 2-agonist with prolonged duration of action.

Authors:  J Lötvall; N Svedmyr
Journal:  Lung       Date:  1993       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.